BioCardia receives Nasdaq deficiency notice for bid price below $1.00

BioCardia, Inc.

Received Nasdaq notice on Aug 19, 2026; bid price below $1.00 for 30 consecutive business days.
Granted 180 days until Feb 16, 2027 to regain compliance via $1.00+ closing bid for 10 straight days.
No immediate impact on listing; company may pursue reverse stock split if needed.
Failure to cure could lead to delisting, with eligibility for additional 180-day period or hearing appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.